Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 198, Issue 11, Pages 1753-1757Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20031030
Keywords
myeloma; vaccine; dendritic cells; prevention; gammopathy
Categories
Funding
- NCI NIH HHS [CA84512, P01 CA084512, CA55819, P01 CA055819] Funding Source: Medline
- NCRR NIH HHS [M01-RR00102, M01 RR000102] Funding Source: Medline
Ask authors/readers for more resources
Most approaches targeting the immune system against tumors have focused on patients with established tumors. However, whether the immune system can recognize preneoplastic stages of human cancer is not known. Here we show that patients with preneoplastic gammopathy mount a vigorous T cell response to autologous premalignant cells. This preneoplasia-specific CD4(+) and CD8(+) T cell response is detected in freshly isolated T cells from the BM. T cells from myeloma marrow lack this tumor-specific rapid effector function. These data provide direct evidence for tumor specific immune recognition in human preneoplasia and suggest a possible role for the immune system in influencing the early growth of transformed cells, long before the development of clinical cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available